Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-73.95%
0%
-73.95%
6 Months
-88.59%
0%
-88.59%
1 Year
-94.09%
0%
-94.09%
2 Years
-98.62%
0%
-98.62%
3 Years
-99.18%
0%
-99.18%
4 Years
-99.66%
0%
-99.66%
5 Years
-99.48%
0%
-99.48%
Carmat SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
51.46%
EBIT Growth (5y)
-7.43%
EBIT to Interest (avg)
-18.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.31
Sales to Capital Employed (avg)
0.27
Tax Ratio
3.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.12
EV to EBIT
-1.20
EV to EBITDA
-1.24
EV to Capital Employed
4.61
EV to Sales
10.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-383.08%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Bearish
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
2.80
0.30
833.33%
Operating Profit (PBDIT) excl Other Income
-52.50
-50.40
-4.17%
Interest
3.10
3.80
-18.42%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-53.90
-53.70
-0.37%
Operating Profit Margin (Excl OI)
-18,750.00%
-150,881.20%
13,213.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 833.33% vs -86.36% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -0.37% vs 13.25% in Dec 2022
About Carmat SA 
Carmat SA
Pharmaceuticals & Biotechnology
Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.
Company Coordinates 
Company Details
36, Avenue de l'Europe, Immeuble l'Etendard VELIZY VILLACOUBLAY None : 78140
Registrar Details






